A worse overall survival was observed in MUC4-overexpressing patients with biliary tract carcinoma (HR 2.41), pancreatic cancer (HR 2.01), and colorectal cancer (HR 1.73). This evidence concerns the gene MUC4 and familial pancreatic carcinoma.